title: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.
abstract: Clinical research examining the role of hematopoietic stem cell transplantation (HSCT) in the therapy of acute myelogenous leukemia (AML) in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts. The identified priority areas of needed future research in adult AML include: (1) What is the role of HSCT in treating patients with specific molecular markers (eg, FLT3, NPM1, CEBPA, BAALC, MLL, NRAS, etc.) especially in patients with normal cytogenetics? (2) What is the benefit of using HSCT to treat different cytogenetic subgroups? (3) What is the impact on survival outcomes of reduced intensity or nonmyeloablative versus conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?
authors.affiliation: Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
authors.forename: Denise M
authors.initials: DM
authors.lastname: Oliansky
authors.forename: Frederick
authors.initials: F
authors.lastname: Appelbaum
authors.forename: Peter A
authors.initials: PA
authors.lastname: Cassileth
authors.forename: Armand
authors.initials: A
authors.lastname: Keating
authors.forename: Jamie
authors.initials: J
authors.lastname: Kerr
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Susan
authors.initials: S
authors.lastname: Stewart
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Philip L
authors.initials: PL
authors.lastname: McCarthy
authors.forename: Theresa
authors.initials: T
authors.lastname: Hahn
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D000090243:Nucleophosmin; D039781:PubMed
chemical_list: D000970:Antineoplastic Agents; C000716967:NPM1 protein, human; D000090243:Nucleophosmin